Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases

被引：0
|
作者：
Yamagata, A. [1 ]
Yokoyama, T. [1 ]
Fukuda, Y. [1 ]
Ishida, T. [1 ]
机构：
[1] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1307P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
    Matos, Ignacio
    Martin-Liberal, Juan
    Garcia-Ruiz, Alonso
    Hierro, Cinta
    Ochoa de Olza, Maria
    Viaplana, Cristina
    Azaro, Analia
    Vieito, Maria
    Brana, Irene
    Mur, Gemma
    Ros, Javier
    Mateos, Jose
    Villacampa, Guillermo
    Berche, Roger
    Oliveira, Mafalda
    Alsina, Maria
    Elez, Elena
    Oaknin, Ana
    Munoz-Couselo, Eva
    Carles, Joan
    Felip, Enriqueta
    Rodon, Jordi
    Tabernero, Josep
    Dienstmann, Rodrigo
    Perez-Lopez, Raquel
    Garralda, Elena
    CLINICAL CANCER RESEARCH, 2020, 26 (08) : 1846 - 1855
  • [42] Economic sustainability of immune-checkpoint inhibitors: the looming threat
    Verma, Vivek
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) : 721 - 722
  • [43] Immune-Checkpoint Inhibitors in B-Cell Lymphoma
    Armengol, Marc
    Santos, Juliana Carvalho
    Fernandez-Serrano, Miranda
    Profitos-Peleja, Nuria
    Ribeiro, Marcelo Lima
    Roue, Gael
    CANCERS, 2021, 13 (02) : 1 - 41
  • [44] A reality check of the accelerated approval of immune-checkpoint inhibitors
    Jennifer Gill
    Vinay Prasad
    Nature Reviews Clinical Oncology, 2019, 16 : 656 - 658
  • [45] Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?
    George Lau
    Ming-Lung Yu
    Grace Wong
    Alexander Thompson
    Hepatology International, 2022, 16 : 482 - 483
  • [46] Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
    Cui, Tian-ming
    Liu, Yao
    Wang, Jia-bei
    Liu, Lian-xin
    ONCOTARGETS AND THERAPY, 2020, 13 : 11725 - 11740
  • [47] The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy
    Ghidini, Michele
    Fusco, Nicola
    Salati, Massimiliano
    Khakoo, Shelize
    Tomasello, Gianluca
    Petrelli, Fausto
    Trapani, Dario
    Petrillo, Angelica
    CURRENT DRUG TARGETS, 2021, 22 (09) : 1021 - 1033
  • [48] Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors
    Yanai, Shunichi
    Toya, Yosuke
    Sugai, Tamotsu
    Matsumoto, Takayuki
    DIGESTION, 2021, 102 (06) : 965 - 973
  • [49] Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors
    Mukharesh, Loulwah
    Chwalisz, Bart K.
    SEMINARS IN OPHTHALMOLOGY, 2021, 36 (04) : 241 - 249
  • [50] Economic sustainability of immune-checkpoint inhibitors: the looming threat
    Vivek Verma
    Nature Reviews Clinical Oncology, 2018, 15 : 721 - 722
12345